PPAR gamma activation Clinical evidence

Slide lecture program (6 slides): View & Download

1. Evolution of clinical evidence supporting PPAR gamma activation
2. Anticipated results from large multicenter trials in (pre)diabetes
3. PROactive: Study Design
4. PROactive Baseline Characteristics
5. PROactive CV history at baseline
6. PROactive CV medications at baseline
7. Time to primary composite endpoint
8. Significant reduction in secondary outcome
9. Time to all-cause death, non-fatal MI, stroke or ACS
10. Time to permanent insulin use
11. PROactive Subgroup analysis – Previous MI
12. PROactive Subgroup analysis – Previous stroke
13. PROactiveHF hospitalization and mortality
14. TZDs associated with lower mortality
15. PROactive in perspective
16. PROactive vs landmark clinical trials: Comparative benefit in patients with diabetes

634919547466080000-Download PPAR section 8 (PPTX 430KB)

PPAR gamma activation Clinical evidence	Evolution of clinical evidence supporting PPAR gamma activation
Anticipated results from large multicenter trials in (pre)diabetes	PROactive: Study Design
PROactive Baseline Characteristics	PROactive CV history at baseline
PROactive CV medications at baseline	Time to primary composite endpoint
Significant reduction in secondary outcome	Time to all-cause death, non-fatal MI, stroke or ACS
Time to permanent insulin use	PROactive Subgroup analysis – Previous MI
PROactive Subgroup analysis – Previous stroke	PROactiveHF hospitalization and mortality
TZDs associated with lower mortality	Summary
PROactive in perspective	PROactive vs landmark clinical trials